News
-
-
COMMUNIQUÉ DE PRESSE
Adolore BioTherapeutics to Present at the Virtual Investor Pitch Conference
Adolore BioTherapeutics to present at Virtual Investor Pitch Conference on June 17, 2024, 10:00 AM ET. CEO Roelof Rongen to provide an elevator pitch on breakthrough opioid-free gene therapy treatments for chronic pain -
-
-
COMMUNIQUÉ DE PRESSE
Adolore BioTherapeutics Outlines Strategy for its Next Generation, Disease-Modifying, Non-Opioid Analgesic Gene Therapies for the Treatment of Chronic Pain
Adolore BioTherapeutics outlines pipeline development progress and business outlook focused on breakthrough gene therapy treatments for chronic pain, funded by NIH grant -
-
-
COMMUNIQUÉ DE PRESSE
Adolore BioTherapeutics Announces Publication Demonstrating Carbonic Anhydrase-8 Gene Therapy (rdHSV-CA8) Decreased Pain-Sensing Neuronal Excitability by Activating Kv7 Voltage-Gated Potassium Channels
Adolore BioTherapeutics announces groundbreaking findings in gene therapy for chronic pain treatment, highlighting the value of non-opioid analgesics and progress with IND-enabling studies -
-
